% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Berger:127996,
      author       = {A.-K. Berger$^*$ and H. M. Singh and W. Werft and A.
                      Muckenhuber and M. Sprick$^*$ and A. Trumpp$^*$ and W.
                      Weichert and D. Jäger$^*$ and C. Springfeld},
      title        = {{H}igh prevalence of incidental and symptomatic venous
                      thromboembolic events in patients with advanced pancreatic
                      cancer under palliative chemotherapy: {A} retrospective
                      cohort study.},
      journal      = {Pancreatology},
      volume       = {17},
      number       = {4},
      issn         = {1424-3903},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2017-04018},
      pages        = {629 - 634},
      year         = {2017},
      abstract     = {Pancreatic cancer patients are at high risk for venous
                      thromboembolic events (VTEs), and chemotherapy is a known
                      additional risk factor. In this context, there is a
                      controversial discussion whether prophylactic
                      anticoagulation should be offered to all outpatients
                      receiving chemotherapy.In this retrospective study, we
                      analyzed incidental and symptomatic VTEs in 150 pancreatic
                      cancer patients receiving either gemcitabine-based
                      chemotherapy or chemotherapy according to the FOLFIRINOX
                      protocol.VTEs were identified in $25\%$ of patients, but
                      were not associated with an adverse survival. There was no
                      significant difference in VTE incidence between patients
                      treated with gemcitabine-based chemotherapy or the more
                      intensive FOLFIRINOX protocol. A commonly used risk score to
                      predict VTEs in cancer patients did not predict the
                      occurrence of VTEs in our patients. The occurrence of VTEs
                      was not associated with one of the recently described
                      pancreatic cancer subtypes.One quarter of pancreatic cancer
                      patients treated with palliative chemotherapy develops
                      symptomatic or incidental VTEs that cannot be predicted by
                      type of chemotherapy, subtype of pancreatic cancer or a
                      commonly used risk score. Further studies are necessary to
                      identify patients at risk, and to better define which
                      patients at risk should be treated with prophylactic
                      anticoagulation.},
      cin          = {V964 / A010 / D120 / L101 / L701},
      ddc          = {610},
      cid          = {I:(DE-He78)V964-20160331 / I:(DE-He78)A010-20160331 /
                      I:(DE-He78)D120-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)L701-20160331},
      pnm          = {319H - Addenda (POF3-319H)},
      pid          = {G:(DE-HGF)POF3-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28462862},
      doi          = {10.1016/j.pan.2017.04.012},
      url          = {https://inrepo02.dkfz.de/record/127996},
}